199 related articles for article (PubMed ID: 7597305)
21. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
[TBL] [Abstract][Full Text] [Related]
22. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
Bernengo MG; Doveil GC; Bertero M; Quaglino P; Fierro MT; Savoia P; Appino A; Colonna S
Melanoma Res; 1996 Jun; 6(3):257-65. PubMed ID: 8819129
[TBL] [Abstract][Full Text] [Related]
23. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
Lopez M; Carpano S; Cavaliere R; Di Lauro L; Ameglio F; Vitelli G; Frasca AM; Vici P; Pignatti F; Rosselli M
Ann Oncol; 1994 Oct; 5(8):741-6. PubMed ID: 7826907
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of malignant melanoma at the stage of distant metastasis].
Garbe C; Eigentler TK
Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
[TBL] [Abstract][Full Text] [Related]
25. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Thompson JA; Gold PJ; Fefer A
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.
Proebstle TM; Fuchs T; Scheibenbogen C; Sterry W; Keilholz U
Melanoma Res; 1998 Dec; 8(6):557-63. PubMed ID: 9918418
[TBL] [Abstract][Full Text] [Related]
27. Treatment of metastatic malignant melanoma.
Atallah E; Flaherty L
Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
[TBL] [Abstract][Full Text] [Related]
28. The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
Punt CJ
Melanoma Res; 1998 Apr; 8(2):95-104. PubMed ID: 9610861
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Ridolfi R; Chiarion-Sileni V; Guida M; Romanini A; Labianca R; Freschi A; Lo Re G; Nortilli R; Brugnara S; Vitali P; Nanni O;
J Clin Oncol; 2002 Mar; 20(6):1600-7. PubMed ID: 11896110
[TBL] [Abstract][Full Text] [Related]
30. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
31. Metastatic melanoma.
Sun W; Schuchter LM
Curr Treat Options Oncol; 2001 Jun; 2(3):193-202. PubMed ID: 12057119
[TBL] [Abstract][Full Text] [Related]
32. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
[TBL] [Abstract][Full Text] [Related]
33. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2.
Heywood GR; Rosenberg SA; Weber JS
J Natl Cancer Inst; 1995 Jun; 87(12):915-22. PubMed ID: 7666481
[TBL] [Abstract][Full Text] [Related]
34. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
35. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M; Caubet JF; McGarry R
Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
[TBL] [Abstract][Full Text] [Related]
36. Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Richards JM; Mehta N; Ramming K; Skosey P
J Clin Oncol; 1992 Aug; 10(8):1338-43. PubMed ID: 1634924
[TBL] [Abstract][Full Text] [Related]
37. Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Chapman PB; Panageas KS; Williams L; Wolchok JD; Livingston PO; Quinn C; Hwu WJ
Melanoma Res; 2002 Aug; 12(4):381-7. PubMed ID: 12170188
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
[TBL] [Abstract][Full Text] [Related]
39. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
Khayat D; Coeffic D
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]